A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma
EGFR Positive Non-small Cell Lung Cancer

Interventions

DRUG: EGFR-TKI
RADIATION: Thoracic Hypofractionated Radiotherapy

Sponsor

First People's Hospital of Hangzhou